Several reasons can be attributed to this: Firstly, there is a possibility of poor adherence to oral medications, especially among those taking combination and multiple therapies, not only for hyperglycaemia but also for other comorbidities [26, 38, 39].
The framework allows for concurrent annealing, particle size reduction and the possibility of ash adherence to the particle surface, although the latter two submodels require the specification of several parameters.
Combining this finding with the possibility of lower adherence over longer screening intervals, 5 year screening intervals may be even more attractive.
Managing multiple long-term conditions often involves polypharmacy, potentially increasing complexity and the possibility of poor adherence.
The possibility of poor adherence to titration of insulin was minimized by requiring participants to have, in addition to HbA1c >7.0%, at least moderate control of FPG (≤7.8 mmol/L).
However, about 30% of subjects in the good adherence group were identified as having the high possibility of non-adherence (false-positive).
An important barrier to in-depth adherence communication was that some physicians felt it was awkward to explore the possibility of non-adherence if there were no objective signs of treatment failure, because patients could feel "accused".
Clearly, there is a need to develop a screening instrument to assess the high possibility of non-adherence using a comprehensive, theoretical model.
Adherence problems lead to suboptimal control of hypertension in two ways: the patient does not take medications as prescribed and the possibility of non-adherence increases the uncertainty faced by physicians in deciding medication changes [ 7, 8].
Polypharmacy, the prescribing of multiple medications to the same individual, increases the risk of adverse drug events [ 5, 6], and increases the complexity of a regimen and thus the possibility of non-adherence [ 7].
